Sports Nutrition Company Names Brand Innovator Matthew Kerbel as Chief Marketing Officer; Adds Finance Expert Paul Anton as VP of Finance
DENVER, July 20, 2017 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, today announced that it had bolstered its executive team with the addition of Matthew Kerbel and Paul Anton as Chief Marketing Officer and Vice President of Finance, respectively. Both will join the Company in early August.
In his new role as Chief Marketing Officer, Mr. Kerbel will be responsible for directing and executing brand strategy to support MusclePharm's growth both domestically and internationally, continuing to engage the Company's core audience, while identifying innovative ways to reach a growing cohort of vegan and recreational athletes. As part of this, Mr. Kerbel will support the expansion of the recently-launched Natural Series product line, a range of all-natural, plant-based, certified organic sports nutrition products. Additionally, he will oversee the management and implementation of all current and future brand athlete and influencer agreements.
"Matt harbors a deep understanding of the messages and values that resonate with our target audiences," said Ryan Drexler, President and CEO of MusclePharm. "Moreover, he truly cares about delivering an excellent and authentic product. His enthusiasm for the fitness industry combined with his notable expertise in conceptualizing and implementing impactful consumer marketing strategies, make him an ideal fit for MusclePharm."
Mr. Kerbel's career has included senior marketing roles, where he was responsible for driving significant growth, at both emerging consumer brands such as Lyft and Juicero, as well as major corporations like Activision and General Mills. He has a proven track-record of formulating and executing impactful multi-channel marketing efforts. Mr. Kerbel earned his Bachelor of Commerce from McGill University in Montreal, and his Master of Business Administration from UCLA's Anderson School of Management.
"The opportunity to join MusclePharm is congruous with my passion for working with dynamic and forward-thinking businesses," said Mr. Kerbel. "MusclePharm is already a global company with strong brand equity and, as evidenced by the recent launch of the Natural Series, is highly attuned to the evolving needs of consumers. The Company has reached a critical inflection point in its history, and this is therefore an extremely exciting time for me to come on board."
As Vice President of Finance, Paul Anton will be responsible for directing all accounting operations, SEC reporting, identifying key revenue and cost drivers and ensuring budgetary compliance. Working alongside the MusclePharm executive team, he will implement robust financial planning and reporting procedures, provide strategic guidance to secure capital and support the Company's growth objectives.
Prior to joining MusclePharm, Mr. Anton served as Vice President of Finance at Bradshaw International, Inc., the largest homewares supplier in the world. In this role, he successfully spearheaded multiple acquisitions, implemented numerous business-efficient systems and workflow processes, and oversaw all corporate accounting and reporting. He is a Certified Public Accountant, having received his Bachelor of Science in Accounting from the University of Redlands.
"Paul proved himself to be a critical factor in Bradshaw's success, and yields a wealth of relevant and valuable experience. He holds an impressive track record in formulating, implementing and evaluating key processes to achieve organizational goals, and we are confident that he can draw from this skillset to help MusclePharm operate even more effectively," noted Mr. Drexler.
Mr. Anton added, "In joining MusclePharm, I look forward to working with a group of talented individuals that are not only leaders in the sports nutrition industry but are equally committed to achieving long-term success for the Company and its shareholders. I am confident that MusclePharm is well-positioned to achieve tremendous growth, and I look forward to playing an important role in this effort."
About MusclePharm Corporation
MusclePharm® is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. Its portfolio of recognized brands includes MusclePharm® Sport Series, Black Label and Core Series, FitMiss™, as well as Natural Series which was launched in 2017. These products are available in more than 120 countries and over 50,000 retail outlets worldwide. The clinically-proven supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
SOURCE MusclePharm Corporation
Released July 20, 2017